Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
160
Tumor Immunotherapy01:27

Tumor Immunotherapy

522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

198
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

274
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
274
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

246
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
246
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of resistance training performed to repetition non-failure on exercise performance in healthy adults: a systematic review and meta-analysis.

BMC sports science, medicine & rehabilitation·2026
Same author

Paederoside alleviates rheumatoid arthritis by targeting SMAD4 to suppress histone lactylation through inhibiting lactate transport in senescent macrophages.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Calceolarioside B alleviates airway barrier dysfunction and inflammation via targeting P2Y<sub>6</sub>R in OVA-triggered asthma.

Biochemical pharmacology·2026
Same author

Accumulation of Histidine Reduce the Susceptibility of Vibrio splendidus Persister Cells to Tetracycline.

Environmental microbiology reports·2026
Same author

Microviscosity-gated excited-state partitioning in a NIR-II molecular rotor for disease imaging and imaging-guided photothermal therapy.

Materials today. Bio·2026
Same author

Editorial: The application of complex training in sports: theory, practice, and impact.

Frontiers in sports and active living·2026

Related Experiment Video

Updated: Jun 29, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K

A Novel Coacervate Embolic Agent for Tumor Chemoembolization.

Menghui Liu1,2,3, Yang Sun1,2,3, Yitong Zhou1,2

  • 1Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, 519000, China.

Advanced Healthcare Materials
|April 8, 2024
PubMed
Summary

This study introduces a novel coacervate embolic agent for transcatheter arterial chemoembolization (TACE). The new agent effectively delivers chemotherapy drugs, showing promise for improved tumor treatment.

Keywords:
VX2 tumorcoacervateliquid embolic agenttranscatheter arterial chemoembolization

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.5K

Related Experiment Videos

Last Updated: Jun 29, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.5K

Area of Science:

  • Biomaterials Science
  • Oncology
  • Interventional Radiology

Background:

  • Traditional transcatheter arterial chemoembolization (TACE) agents have limitations in drug loading, sustained release, biodegradability, and mechanical stability.
  • Existing agents often struggle with aggregation and unstable properties, hindering optimal therapeutic outcomes.

Purpose of the Study:

  • To develop and evaluate a novel complex coacervate-based liquid embolic agent for improved tumor chemoembolization.
  • To address the limitations of traditional TACE agents by enhancing drug delivery and sustained release.

Main Methods:

  • A complex coacervate was formed by mixing quaternized chitosan (QCS) and gum arabic (GA), exhibiting shear-thinning properties.
  • Iohexol (I) and doxorubicin (DOX) were incorporated into the QCS/GA coacervate to create an X-ray-opaque, drug-carrying embolic agent (QCS/GA/I/DOX).
  • The agent's efficacy was tested in embolizing renal arteries and VX2 tumor-supplying arteries in rabbit models.

Main Results:

  • The QCS/GA/I/DOX coacervate demonstrated effective embolization of renal arteries without recanalization.
  • Successful embolization of VX2 tumor-feeding arteries in rabbit ear and liver models was achieved.
  • The coacervate facilitated local doxorubicin release, enhancing antitumor efficacy with excellent biocompatibility and biodegradability.

Conclusions:

  • The novel QCS/GA/I/DOX coacervate embolic agent offers superior drug-loading and sustained-release capabilities compared to traditional agents.
  • This innovative formulation shows significant potential for effective and safe tumor chemoembolization with user-friendly application.
  • The shear-thinning property, biocompatibility, and biodegradability make this coacervate a promising advancement in cancer therapy.